Valneva receives first marketing authorization for ixchiq® in a chikungunya endemic country

Saint herblain (france), april 14, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company today announced that the brazilian health regulatory agency (anvisa) has granted marketing authorization to its single-dose vaccine ixchiq® for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. the anvisa decision marks the world's first approval of a chikungunya vaccine in an endemic country. part of valneva's endemic country strategy, this endeavor is supported by the coalition for epidemic preparedness innovations (cepi)1, with co-funding from the european union (eu), and instituto butantan2 to support broader access to a chikungunya vaccine in low-and-middle-income countries (lmics).
VALN Ratings Summary
VALN Quant Ranking